P2RY1 and Stroke: These data, together with those of Hankey et al. in his Cochrane review published roughly at the same time on the modestly but significantly better efficacy of ADP-receptor antagonists as compared with aspirin in stroke patients [18] constituted a valid reason for all those neurologist involved in MATCH to try to offer their patients with stroke something more effective than aspirin monotherapy.